Objective: To clarify how easily can entacapone (ENT) be switched to opicapone (OPC), in levodopa-treated patients with Parkinson’s disease (PD) and motor-fluctuations.

Background: OPC, a new once-daily COMT inhibitor, was shown to be effective in the treatment of motor fluctuations in Parkinson’s disease patients.

Methods: Switch data from the double-blind (DB) to the open-label (OL) phase of a Phase-III, multicentre, randomised, placebo- and active-controlled, parallel-group study. In the DB phase, ENT patients took each ENT dose concomitantly with each levodopa daytime dose. OPC patients took each OPC dose as an additional bedtime dose administered at least 1 hour after the last daily dose of levodopa. In the 52-week OL phase, all patients received a bedtime daily-dose of 25mg OPC for the first week and thereafter OPC and levodopa doses were adjusted according to clinical response except on last month when both were to remain stable.

Results: A total of 122 patients were randomized to ENT. On the last visit of the DB phase, ENT patients took each ENT dose concomitantly with each levodopa daytime dose and the OL OPC dose, in the same day, as an additional bedtime dose administered at least 1 hour after the last daily dose of levodopa. On the following days, patients took each levodopa daytime dose alone and the OL OPC dose as the additional bedtime dose. Switch from ENT to OPC was considered safe and well tolerated with an immediate improvement of the OFF-time reduction.

Conclusions: Overnight switch from ENT to OPC was considered safe and well tolerated with an immediate improvement of the OFF-time reduction.

« Back to 2017 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/how-to-switch-from-entacapone-to-opicapone-based-on-bipark-i-study-experience/